We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
S&P Global (SPGI) Touches 52-Week High: What's Driving It?
Read MoreHide Full Article
Shares of S&P Global Inc. (SPGI - Free Report) scaled a 52-week high of $357.07 in the trading session on Jul 15, before closing a tad lower at $354.80.
The company’s shares have charted a solid trajectory, appreciating 29.9% year to date, ahead of 13.5% growth of the industry it belongs to and in contrast to 0.5% decline of the Zacks S&P 500 composite.
Notably, S&P Global has witnessed a 19.9% rise in share price since it posted first-quarter 2020 results.
Let’s find out what’s supporting the uptick.
Consecutive Earnings & Revenue Beat
S&P Global reported back-to-back earnings and revenue beat in the last four quarters. While the bottom line continued to gain from revenue growth and benefits of productivity initiatives, the top line performed well on the back of strength across all segments, namely S&P Global Ratings, S&P Global Market Intelligence, S&P Global Platts and S&P Dow Jones Indices.
Rising Demand for Business Information Services
S&P Global is gaining from rising demand for business-information services. Constantly increasing volume of data from private and government organizations has augmented demand for improved enterprise-wide financial-performance visibility. Higher demand for news, information, and analytics solutions will drive the market’s growth. Further, the industry is benefiting from rising demand for risk mitigation. Changes in market dynamics are more or less a constant phenomenon and expose companies to credit fund as well as operational risks. Accurate market and financial information is required for risk mitigation, thereby spurring demand for business-information services.
Strategic Acquisitions Bode Well
Acquisitions have been a key growth strategy for S&P Global, helping it continuously innovate, increase differentiated content and develop new products.
In January 2020, the company completed the acquisition of ESG Ratings Business (from RobecoSAM), thus boosting its position as a premier resource for essential ESG Data, ratings, benchmarks and insights. In 2019, the company acquired 451 Research, Canadian Enerdata, Live Rice Index and Orion technology center. 451 Research is likely to strengthen S&P Global Market Intelligence's emerging technology expertise and offerings. Canadian Enerdata enhances S&P Global Platts division's energy analytical capabilities and strengthens its foothold in the North American natural gas market. Live Rice Index is a great addition to Platts’ global agriculture offering. Orion technology center provides the company’s employees with access to the latest technologies and global communications infrastructure.
The company is expected to continue adding advanced technology and data sets through acquisitions, which in turn should boost its top- and bottom-line growth.
Zacks Rank and Stocks to Consider
S&P Global currently carries a Zacks Rank #3 (Hold).
The long-term expected earnings per share (three to five years) growth rate for DocuSign, SailPoint and ManpowerGroup is 31.2%, 15% and 1.5%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
S&P Global (SPGI) Touches 52-Week High: What's Driving It?
Shares of S&P Global Inc. (SPGI - Free Report) scaled a 52-week high of $357.07 in the trading session on Jul 15, before closing a tad lower at $354.80.
The company’s shares have charted a solid trajectory, appreciating 29.9% year to date, ahead of 13.5% growth of the industry it belongs to and in contrast to 0.5% decline of the Zacks S&P 500 composite.
Notably, S&P Global has witnessed a 19.9% rise in share price since it posted first-quarter 2020 results.
Let’s find out what’s supporting the uptick.
Consecutive Earnings & Revenue Beat
S&P Global reported back-to-back earnings and revenue beat in the last four quarters. While the bottom line continued to gain from revenue growth and benefits of productivity initiatives, the top line performed well on the back of strength across all segments, namely S&P Global Ratings, S&P Global Market Intelligence, S&P Global Platts and S&P Dow Jones Indices.
Rising Demand for Business Information Services
S&P Global is gaining from rising demand for business-information services. Constantly increasing volume of data from private and government organizations has augmented demand for improved enterprise-wide financial-performance visibility. Higher demand for news, information, and analytics solutions will drive the market’s growth. Further, the industry is benefiting from rising demand for risk mitigation. Changes in market dynamics are more or less a constant phenomenon and expose companies to credit fund as well as operational risks. Accurate market and financial information is required for risk mitigation, thereby spurring demand for business-information services.
Strategic Acquisitions Bode Well
Acquisitions have been a key growth strategy for S&P Global, helping it continuously innovate, increase differentiated content and develop new products.
In January 2020, the company completed the acquisition of ESG Ratings Business (from RobecoSAM), thus boosting its position as a premier resource for essential ESG Data, ratings, benchmarks and insights. In 2019, the company acquired 451 Research, Canadian Enerdata, Live Rice Index and Orion technology center. 451 Research is likely to strengthen S&P Global Market Intelligence's emerging technology expertise and offerings. Canadian Enerdata enhances S&P Global Platts division's energy analytical capabilities and strengthens its foothold in the North American natural gas market. Live Rice Index is a great addition to Platts’ global agriculture offering. Orion technology center provides the company’s employees with access to the latest technologies and global communications infrastructure.
The company is expected to continue adding advanced technology and data sets through acquisitions, which in turn should boost its top- and bottom-line growth.
Zacks Rank and Stocks to Consider
S&P Global currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are DocuSign (DOCU - Free Report) , SailPoint Technologies Holdings, Inc. and ManpowerGroup (MAN - Free Report) . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The long-term expected earnings per share (three to five years) growth rate for DocuSign, SailPoint and ManpowerGroup is 31.2%, 15% and 1.5%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>